Articles tagged "Rejection"

2018 American Transplant Congress
Genome-Wide Association Study Assessing Risk of Rejection in Pediatric Transplant Recipients
T. Papaz,¹ S. Min,¹ O. Lee,¹ T. Blydt-Hansen,³ U. Allen,¹ Y. Avitzur,¹ P. Birk,² B. Foster,⁴ H. Grasemann,¹ L. Hamiwka,⁵ R. Parekh,¹ V. Phan,⁶ S. Urschel,⁷ S. Mital.¹
¹SickKids Hospital, Toronto, ON, Canada; ²Winnipeg Children's Hospital, Winnipeg, MB, Canada; ³BC Children's Hospital, Vancouver, BC, Canada; ⁴Montreal Children's Hospital, Montreal, QC, Canada; ⁵Alberta Children's Hospital, Calgary, AB, Canada; ⁶CHU Sainte Justines, Montreal, QC, Canada; ⁷Stollery Children's Hospital, Edmonton, AB, Canada.
Background: Rejection risk varies after solid organ transplantation (SOT). We explored genomic variants associated with susceptibility to graft rejection.Methods: SOTs enrolled in a multicenter prospective…
2018 American Transplant Congress
The Efficacy and Safety of Rituximab as Induction Therapy in Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials
X. Wang,¹ J. Chen,² X. Tu,² Y. Qiu,¹ T. Song,¹ T. Lin.¹
¹Department of Urology/Institute of Urology/Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China; ²West China School of Clinical Medicine, Sichuan University, Chengdu, Sichuan Province, China.
Objectives. This meta-analysis was undertaken to assess the efficacy and safety of rituximab as induction therapy in kidney transplantation.Methods. OVID, Embase, SCI, PubMed and EBSCO…
2018 American Transplant Congress
AMD3100 (Plerixafor) as a Single-Dose Stem Cell Mobilizing Agent in Vascularized Composite Tissue Allograft (VCA) Transplantation in a Canine Model
B. Swearingen,^1,2 S. Graves,^2,3 R. Storb,^2,3 D. Mathes.^1,2
¹Surgery; Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine, Aurora, CO; ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Medicine, University of Washington Medical Center, Seattle, WA.
PURPOSE:Vascularized Composite Allograft (VCA) transplantation is a clinical reality but limited by chronic immunosuppression and rejection. Current clinical tolerance protocols rely on recipient conditioning and…
2018 American Transplant Congress
12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients
M. Matignon,¹ C. Dudreuilh,¹ P. Rémy,¹ J-.L. Taupin,² P. Grimbert.¹
¹Nephrology Transplantation, APHP Henri Mondor, Creteil, France; ²Histocompatibility, APHP Saint Louis, Paris, France.
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…
2018 American Transplant Congress
Monitoring of Small Bowel Allografts with Kynurenine Serum Levels
M. Stangl,¹ D. Koliogiannis,¹ J. Bucher,¹ M. Guba,¹ D. Abendroth.²
¹Transplant Center Munich, Klinikum Großhadern, LMU Munich, Munich, Germany; ²Department of Surgery, University of Ulm, Ulm, Germany.
Long-term success in intestinal transplantation could be significantly improved by the development of a reliable noninvasive marker of rejection, allowing early diagnosis and treatment without…
2018 American Transplant Congress
Clinically Relevant Variation of Donor-Derived Cell-Free DNA during Longitudinal Surveillance of Renal Allografts
M. Narayanan,¹ T. Alhamad,² D. Hiller,³ J. Yee,³ R. Woodward,³ J. Bromberg.⁴
¹Texas A&M Health Science Center, Temple, TX; ²Washington University School of Medicine, St. Louis, MO; ³CareDx, Brisbane, CA; ⁴University of Maryland School of Medicine, Baltimore, MD.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) levels >1% are associated with active rejection in renal transplant recipients. This report defines the clinically relevant variation of dd-cfDNA…
2018 American Transplant Congress
Development of a Novel Assay System for Ex Vivo T-Cell Mediated Rejection Responses in Intestinal Grafts
S. Okano,^1,2 K. Abu-Elmagd,² D. Kish,¹ K. Keslar,¹ M. Fujiki,² G. Costa,² C. Miller,² W. Baldwin,¹ R. Fairchild,¹ K. Hashimoto.²
¹Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; ²General Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH.
In intestinal transplantation, the intestinal allograft (IA) presents a formidable challenge for control of alloimmune responses due to constitutive MHC class II expression by intestinal…
2018 American Transplant Congress
Thymoglobulin Induction Decreases Risk of Death in HLA-Sensitized Kidney Recipients
C. Loheac, O. Aubert, M. Assayag, D. Viglietti, C. Lefaucheur, A. Loupy.
Paris Translational Research Center for Organ Transplantation, Paris, France.
Anti-thymocyte globulin (ATG) is currently the preferential induction treatment in kidney recipients at high risk for allograft rejection. However, no study has evaluated the benefits…
2018 American Transplant Congress
A Transcriptomic Signature in PBMC from Kidney Transplant Recipients at Baseline Predicts Early Acute Rejection
W. Zhang,¹ Z. Yi,¹ P. Cravedi,¹ L. Li,¹ K. Keung,² C. Wei,¹ M. Menon,¹ J. Dudley,¹ P. O'Connell,² B. Murphy.¹
¹Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; ²Medicine, The University of Sydney, Sydney, Australia.
Background: Our multi-center study (Genomics of Chronic Allograft Rejection, GoCAR) revealed that early acute rejection (EAR, developed before 6 months post-transplant) is associated with later…
2018 American Transplant Congress
A Novel Peripheral Blood mRNA Biomarker Predicts Subclinical Rejection and Kidney Transplant Outcomes
J. Friedewald,¹ S. Kurian,² T. Whisenant,² R. Heilman,³ E. Poggio,⁴ C. Marsh,² P. Baliga,⁵ N. Bridges,⁶ J. Odim,⁶ M. Brown,⁶ D. Ikle,⁷ B. Armstrong,⁷ J. Charette,¹ S. Brietigam,¹ N. Sustento-Reodica,¹ L. Zhao,¹ M. Kandpal,¹ D. Salomon,² M. Abecassis.¹
¹Northwestern Medicine, Chicago; ²Scripps, La Jolla; ³Mayo AZ, Scottsdale; ⁴Cleveland Clinic, Cleveland; ⁵MUSC, Charleston; ⁶NIAID, Bethesda; ⁷Rho, Chapel Hill.
BACKGROUNDSub-clinical acute rejection (subAR) in kidney transplant recipients (KTR), defined as histological rejection on surveillance biopsy (Bx) in a patient with stable renal function, signals…